Feb 10, 2024 | Business
Daugherty Business Solutions, a leading advisory services and technology consulting firm, is recognized for enabling and delivering success in helping organizations reimagine their customer experiences in 2023.
Daugherty has been named Breakthrough Partner of the Year by Five9, the provider of the Intelligent CX Platform. The Five9 2023 Global Partner Awards recognize the achievements of the Five9 global ecosystem of channel partners, Systems Integrators, strategic alliance partners, and Independent Software Vendors (ISVs).
Daugherty partners with Five9 to bring clients end to end strategic customer care solutions. This includes multiyear contact center strategic road mapping, full stack technology implementation, cloud migration from legacy platforms, CRM/SFA integration, customer and agent experience transformation, Generative AI solution integration and more.
“As the premier CCaaS solution on the market, Five9 continues to lead the way in helping their customers provide faster, more complete outcomes. Daugherty is committed to helping our clients create their strategy and selection criteria for these tools, and we’ve seen first-hand the power of Five9,” Nathan Orwig, Global VP, Enterprise Strategy, Technology & Innovation at Daugherty, said. “We officially established our partnership in 2023 when we began work with a Fortune 20 company together, and in 2024 we look forward to building upon this foundation and also becoming a Certified Implementation Partner. The sky is truly the limit with what we can accomplish together for our customer care solutions!”
“Our partners consistently provide a high level of value to Five9 and our joint customers. The continued growth we have experienced over the last several years would not have been possible without the global reach and stellar performance of our partners,” said Jake Butterbaugh, Senior Vice President, Global Partners. “These partner award winners represent the best of the best. We are so happy to recognize them and are humbled and inspired by their commitment to Five9 and to delivering outstanding CX. Congratulations, Daugherty, on your well-deserved recognition.”
About Five9
Five9 is on a mission to Bring Joy to CX™. The Five9 Global Partner program and its 1,400+ members deliver excellence, integrity, and solutions that enable our joint customers to deliver exceptional customer experiences. The Five9 Intelligent CX Platform is a leading AI-powered CCaaS solution that elevates contact center performance by empowering managers with actionable insights and intelligence, personalize customer experiences with self-service and their choice of channel to communicate, elevating businesses to deliver results ensuring the delivery of joyful agent and customer experiences.
About Daugherty Business Solutions
For nearly 40 years, Daugherty has been committed to driving innovation, growth and customer satisfaction across the nation while making a positive difference in the community. With software engineering, data analytics, business advisory services, and technology and delivery leadership, Daugherty delivers significant business results quickly and effectively. Leveraging proprietary tools, techniques, and virtual and regional development centers, Daugherty is a preferred strategic advisor and partner for the Fortune 500, helping customers achieve better and more predictable outcomes for mission-critical initiatives.
Jun 15, 2022 | Business
On June 14, two of Legend Capital’s portfolio companies, Innovent Biologics, Inc. (“Innovent”) and PT Etana Biotechnologies Indonesia (“Etana”), jointly announced that the Indonesian Food and Drugs Authority (BPOM) had approved Bevagen (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug for five indications including metastatic colorectal cancer (mCRC), metastatic triple-negative breast cancer (mTNBC), advanced non-small cell lung cancer(NSCLC), ovarian cancer (OC), and cervical cancer(CC). Under the approval of the BPOM, Bevagen will potentially be the first Chinese antibody drug to be marketed and locally produced in Southeast Asia.
Dr. Michael Yu, Founder, Chairman and CEO of Innovent, said, “We are pleased that under the strategic collaboration with Etana, the approval of Bevagen in Indonesia marked a meaningful step toward bringing Innovent’s innovative portfolio into the global market, benefitting patients globally. Pairing Etana’s commercial expertise in the local Indonesian market with Bevagen’s clinical profile, high-quality production and relative affordability, we are confident that Bevagen will launch to the market quickly and benefit many cancer patients.”
Nathan Tirtana, President Director of Etana, said, “Etana appreciates the support of BPOM for approving Bevagen for cancer patients in Indonesia. With this product, we believe we can provide better access to high-quality and affordable biosimilar drug to meet the need of cancer patients in Indonesia. Our next step is to implement the technology transfer and local Bevagen production in Indonesia via collaboration with Innovent.”
Legend Capital has been looking for investment and partnership opportunities in the Southeast Asian market since 2019 and ultimately invested in Etana in 2020. By leveraging the advantages of the portfolio ecosystem, Legend Capital has played an active role in promoting the strategic cooperation between Innovent and Etana.
Mr. Frank Hong, Managing Director of Legend Capital, said, “Congratulations to Innovent and Etana for the approval of the first biosimilar in Indonesia. This milestone achievement demonstrates the feasibility of expanding Chinese innovative drugs market access into the emerging markets. The emerging markets along the Belt and Road have significant demand for pharmaceutical products and unmet clinical needs, Chinese innovative therapeutics are particularly well suited to the needs of patients in developing countries given their quality and affordable prices. Legend Capital will continue to explore investment opportunities in the emerging markets and actively pioneer the path for Chinese high-end biologics’ overseas expansion, facilitating the globalization of Chinese pharmaceutical companies.”
Mr. Fei Qi, Executive Director of Legend Capital, said, “The cross-border investment and industrial collaboration in the Southeast Asian market possess unique challenges: from policy regulation, folk culture to healthcare system complexity. Etana has set up a competitive barrier of ‘Access + Manufacturing + Commercialization’ in Southeast Asia, and Legend Capital complemented Etana’s key ‘Business Development’ ability by leveraging its healthcare portfolio ecosystem. Legend Capital has provided a series of value-add services in terms of company strategy, business cooperation and subsequent financing to Etana since its investment. Etana has approached and discussed collaboration initiatives with more than 10 Chinese biopharmaceutical companies and plans to introduce more therapeutics that Indonesia currently lacks, such as cancer monoclonal antibodies, COVID vaccines, and antiviral infection drugs. Through the joint efforts of Etana and its partners, we believe that the company will be able to provide high-quality and affordable Chinese innovative drugs to Indonesia, Southeast Asia and even the Islamic world.”
Legend Capital has been firmly positioned to invest systematically in the field of innovative medicine. Adhering to the investment philosophy of “Global Vision, Chinese Insights”, Legend Capital is looking for truly internationally competitive technologies and teams to solve the unmet clinical needs; many of its portfolio companies have been listed on A-share or H-share successfully, such as Kawin Technology (688687.SH), Innovent Biologics (01801.HK), Hbm (02142.HK), Recbio Technology (2179.HK). At the same time, we also made investments in segment-leading companies such as GluBio Pharmaceutical, Ribo Life Science, PegBio, Exegenesis Bio, Lynk Pharmaceuticals and Innostellar Biotherapeutics.
Topic: Press release summary
Aug 25, 2021 | Business
A magazine subscription store-within-a-store will open on a major U.S. retailer’s e-commerce site, says MixMedia, the retailer’s magazine subscription vendor. Launch is expected by end of 2021 and is one of three online magazine stores planned with major U.S. retailers.
The yet to be named retailer is reported to have a significant online presence with well over 20 million unique visitors per month. John Crouse, Managing Partner of MixMedia says, “It’s not often that a new channel of paid subscriptions opens for publishers. Advertisers, consumers, publishers, and the retailer all win. Engaged and paid audiences with great demos are not only good for publishers, but the magazine content also helps drive sales of in-store products for the retailer.”
MixMedia launched in January 2021 by John Crouse. John is a longtime magazine publishing veteran having worked at TV Guide, Reader’s Digest, Time Inc., and most recently EBSCO Industries. MixMedia assists brands in utilizing their content in new ways and helping open new revenue sources for its clients.
Contact